Predicting treatment efficacy by analyzing non-cancer cells
US-2025272835-A1 · Aug 28, 2025 · US
Frampton Garrett Michael is listed as an inventor on 22 patents in our database. Major assignees and classification codes are summarized below.
| Metric | Value |
|---|---|
| Inventor | Frampton Garrett Michael |
| Total patents | 22 |
| First publication | Jul 14, 2016 |
| Latest publication | Aug 28, 2025 |
Publications ranked by popularity score, then publication date.
US-2025272835-A1 · Aug 28, 2025 · US
US-2025146077-A1 · May 8, 2025 · US
US-2024392378-A1 · Nov 28, 2024 · US
US-12116638-B2 · Oct 15, 2024 · US
US-11766439-B2 · Sep 26, 2023 · US
US-11725247-B2 · Aug 15, 2023 · US
US-2022251667-A1 · Aug 11, 2022 · US
US-2022096483-A1 · Mar 31, 2022 · US
US-11286532-B2 · Mar 29, 2022 · US
US-11058687-B2 · Jul 13, 2021 · US
Latest publications not already listed above.
US-2020281930-A1 · Sep 10, 2020 · US
US-2019233897-A1 · Aug 1, 2019 · US
US-2019085403-A1 · Mar 21, 2019 · US
US-2018363066-A1 · Dec 20, 2018 · US
US-2018338977-A1 · Nov 29, 2018 · US
US-2018320238-A1 · Nov 8, 2018 · US
US-10093983-B2 · Oct 9, 2018 · US
US-9907798-B2 · Mar 6, 2018 · US
US-2017016073-A1 · Jan 19, 2017 · US
US-2016375025-A1 · Dec 29, 2016 · US
US-9410954-B2 · Aug 9, 2016 · US
US-2016201135-A1 · Jul 14, 2016 · US
Companies most often associated with this inventor's publications.
| Assignee | Patents |
|---|---|
| Found Medicine Inc | 21 |
| Ucl Business Plc | 5 |
| Univ Vanderbilt | 3 |
| Ucl Business Ltd | 3 |
| Teva Pharma | 1 |
Most common classification codes across this inventor's patents.
| CPC | Patents |
|---|---|
| C12Q1/6886 | 21 |
| C12Q2600/156 | 21 |
| C12Q2600/106 | 20 |
| A61K31/4196 | 17 |
| A61K31/436 | 17 |